| Literature DB >> 32983146 |
Zhengrong Yin1, Jinshuo Fan1, Juanjuan Xu1, Feng Wu1, Yang Li1, Mei Zhou1, Tingting Liao1, Limin Duan1, Sufei Wang1, Wei Geng1, Yang Jin1.
Abstract
Lung cancer represents a fatal condition that has the highest morbidity and mortality among malignancies. The currently available treatments fall short of improving the survival and quality of life of late-stage lung cancer patients. Extracellular vesicles (EVs) secreted by tumors or immune cells transport proteins, lipids, and nucleic acids to other cells, thereby mediating immune regulation in the tumor microenvironment. The cargo carried by EVs vary by cellular state or extracellular milieu. So far, multiple studies have suggested that EVs from lung tumor cells (TEVs) or immune cells promote tumor progression mainly through suppressing antitumor immunity. However, modified or engineered EVs can be used as vaccines to elicit antitumor immunity. In addition, blocking the function of immunosuppressive EVs and using EVs carrying immunogenic medicine or EVs from certain immune cells also shows great potential in lung cancer treatment. To provide information for future studies on the role of EVs in lung cancer immunity, this review focus on the immunoregulatory role of EVs and associated treatment applications in lung cancer.Entities:
Keywords: extracellular vesicles; immunostimulation; immunosuppression; lung cancer; therapeutic application
Mesh:
Substances:
Year: 2020 PMID: 32983146 PMCID: PMC7483575 DOI: 10.3389/fimmu.2020.02024
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561